Endemic Kaposi's Sarcoma

Area of Science:

• Oncology
• Virology
• Dermatology

Background:

• Kaposi's sarcoma (KS) is a neoplasm prevalent in Eastern and Central Africa, strongly associated with human gammaherpesvirus-8 (HHV-8).
• Endemic KS subtypes can exhibit aggressive behavior, including ulcerative skin lesions, soft tissue invasion, and potential bone or visceral involvement.
• The chronic nature of KS necessitates long-term management strategies focused on remission and patient quality of life.

Purpose of the Study:

• To review the clinical course and management of endemic Kaposi's sarcoma.
• To highlight the role of human gammaherpesvirus-8 (HHV-8) in KS pathogenesis.
• To discuss therapeutic options for symptomatic and advanced KS cases.

Main Methods:

• Review of existing literature on Kaposi's sarcoma epidemiology, clinical presentation, and treatment.
• Analysis of the etiological link between HHV-8 and KS development.
• Synthesis of current therapeutic modalities for KS management.

Main Results:

• HHV-8 is identified as a necessary causal agent for KS development.
• Aggressive clinical courses are observed in endemic KS, requiring thorough imaging and follow-up.
• Localized cutaneous KS may be managed with watchful monitoring.

Conclusions:

• Sustainable remission and quality of life are key goals in KS management.
• Advanced symptomatic KS warrants consideration of systemic therapies including chemotherapy, immunomodulators, immune checkpoint inhibitors, and antiangiogenic drugs.
• Effective management requires a multidisciplinary approach tailored to disease extent and patient status.